Human cytomegalovirus (HCMV) UL44 and UL57 specific antibody responses in anti-HCMV-positive patients with systemic sclerosis
- 240 Downloads
The role of human cytomegalovirus (HCMV) has been postulated as a trigger of systemic sclerosis (SSc). The aim of the study was to assess the prevalence of antibodies against HCMV UL44 and UL57 antigens not tested in the past. Sixty SSc patients, 40 multiple sclerosis and 17 normal controls (NCs), all anti-HCMV positive, were tested by immunoblotting. Reactivity to HCMV antigens, expressed as arbitrary units (AUs), was assessed for correlation with clinical and immunological parameters, including types of SSc-related autoantibodies. Anti-UL44 and anti-UL57 HCMV antibodies were present in 3/60 (5%) and 58/60 (96.7%) SSc patients, respectively (p < 0.001). Anti-UL57 antibodies were present in 35/40 (87.5%) MS patients and 16/17 (94.1%) NCs (SSc vs MS, MS vs NC, p = ns). Strong (50-75 AU) and very strong (75–100 AU) anti-UL57 immunoreactivity was found in 24 (41.4%) and 22 (37.9%) SSc patients, respectively (p = ns). Dilution experiments showed anti-UL57 antibody persistence in up to 1/5000. Overall, there was no difference in the frequency or the magnitude of anti-UL57 immunoreactivity between diffuse cutaneous systemic sclerosis and limited cutaneous systemic sclerosis patients (96.67 vs 96.67%; 65.45 ± 20.19 vs 64.31 ± 21.11 AU, p > 0.05) but strong anti-UL57 reactivity were more frequent in SSc compared to NCs (p = 0.007). Anti-UL57 reactivity was not inhibited by SSc-specific autoantigens. Anti-UL57 seropositivity did not correlate with demographic, clinical or immunological features of SSc. Anti-HCMV UL57 antibodies are universally present in anti-HCMV-positive patients with SSc, while those against UL44 are rarely seen. Because anti-UL57 lack disease specificity and are not involved in cross-reactive responses, their immunopathogenetic potential is to be questioned.
KeywordsAutoantibodies Immunology Infections Scleroderma
Diffuse cutaneous systemic sclerosis
Limited cutaneous systemic sclerosis
- RNA pol III
RNA polymerase III
We thank EUROIMMUN, Germany, for providing antigens, kits and reagents.
Compliance with ethical standards
The protocol was approved by the Local Ethical Committee of the University General Hospital of Larissa (no. 1/14-1-2016).
Conflict of interest
T Scheper and W Meyer are employees of Euroimmun; all other authors do not have anything to disclose.
Source of work
Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
ELKE (Research Committee University of Thessaly).
Part of this work was presented as a poster at the 12th Dresden Symposium on Autoantibodies, Germany, September 23–26, 2015, in a study entitled ‘Human cytomegalovirus specific antibody responses in patients with systemic sclerosis’ by C. Liaskos, E. Marou, G. Euthymiou, T. Simopoulou, C. Katsiari, W. Meyer, D.P. Bogdanos and L.I. Sakkas, as presented in Autoantigens, Autoantibodies, Autoimmunity edited by K. Conrad, E.K.L. Chan, L.E.C. Andrade, G. Steiner, G.J.M. Pruijn and Y. Shoenfeld, Pabst Science Publishers (Berlin); vol. 10—2015, p 124
- 2.Chora I, Guiducci S, Manetti M, Romano E, Mazzotta C, Bellando-Randone S, Ibba-Manneschi L, Matucci-Cerinic M, Soares R (2015) Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev 14(4):314–322. doi: 10.1016/j.autrev.2014.12.001 CrossRefPubMedGoogle Scholar
- 15.Elisa T, Antonio P, Giuseppe P, Alessandro B, Giuseppe A, Federico C, Marzia D, Ruggero B, Giacomo M, Andrea O, Daniela R, Mariaelisa R, Claudio L (2015) Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis. J Immunol Res 2015:147616. doi: 10.1155/2015/147616 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Pandey JP, LeRoy EC (1998) Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum 41(1):10–15. doi: 10.1002/1529-0131(199801)41:1<10::AID-ART2>3.0.CO;2-P CrossRefPubMedGoogle Scholar
- 23.Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, Maya R, Shoenfeld Y (2009) The role of infections in the immunopathogensis of systemic sclerosis—evidence from serological studies. Ann N Y Acad Sci 1173:627–632. doi: 10.1111/j.1749-6632.2009.04808.x CrossRefPubMedGoogle Scholar
- 24.Pastano R, Dell’Agnola C, Bason C, Gigli F, Rabascio C, Puccetti A, Tinazzi E, Cetto G, Peccatori F, Martinelli G, Lunardi C (2012) Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease. Int Immunol 24(9):583–591. doi: 10.1093/intimm/dxs061 CrossRefPubMedGoogle Scholar
- 26.Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R, Puccetti A (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6(10):1183–1186. doi: 10.1038/80533 CrossRefPubMedGoogle Scholar
- 28.Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, Tamassia N, Tinazzi E, Beri R, Corrocher R, Puccetti A (2007) Endothelial cells’ activation and apoptosis induced by a subset of antibodies against human cytomegalovirus: relevance to the pathogenesis of atherosclerosis. PLoS One 2(5):e473. doi: 10.1371/journal.pone.0000473 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT (2002) IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2(UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome. Vivo 16(3):153–159Google Scholar
- 30.Efthymiou G, Dardiotis E, Liaskos C, Marou E, Tsimourtou V, Hadjigeorgiou GM, Scheper T, Meyer W, Daponte A, Sakkas LI, Bogdanos DP (2016) Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)relevance to disease pathogenesis. J Neuroimmunol 298:19–23CrossRefPubMedGoogle Scholar
- 32.Neidhart M, Kuchen S, Distler O, Bruhlmann P, Michel BA, Gay RE, Gay S (1999) Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 42(2):389–392. doi: 10.1002/1529-0131(199902)42:2<389::AID-ANR23>3.0.CO;2-P CrossRefPubMedGoogle Scholar
- 35.Riccieri V, Alessandri C, Germano V, Guiducci S, Rogai V, Colasanti T, Delunardo F, Margutti P, Ortona E, Cerinic MM, Valesini G (2010) Nedd5, a novel autoantigen in systemic sclerosis: is it a marker of more severe disease? Ann Rheum Dis 69(1):314–315. doi: 10.1136/ard.2009.111302 CrossRefPubMedGoogle Scholar
- 36.Margutti P, Sorice M, Conti F, Delunardo F, Racaniello M, Alessandri C, Siracusano A, Rigano R, Profumo E, Valesini G, Ortona E (2005) Screening of an endothelial cDNA library identifies the C-terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations. Arthritis Res Ther 7(4):R896–R903. doi: 10.1186/ar1759 CrossRefPubMedPubMedCentralGoogle Scholar